ISSN 1526-5161, 1536-0075
35 papers in the library · 180 citations · publishing 2007-2026
The American Journal of Bioethics September 18, 2026 Liza Dawson, A. S. Cohen, Benjamin S. Wilfond et al. 5 citations
Chronic pain is a significant health problem affecting up to 20% of Americans (Yong et al. 2022), negatively affecting overall health and quality of life, causing disability, and burdening healthca...
The American Journal of Bioethics September 18, 2026 Michelle C. Bach
In the current treatment landscape, psychedelics (here broadly defined to include MDMA, 3,4-methylenedioxymethamphetamine) are under scientific investigation largely for use in chronic and treatmen...
The American Journal of Bioethics September 18, 2026 Rachel J. Topazian, Michael J. DiStefano, Gianna Morales et al.
The case raises questions regarding what constitutes employment-based risks in psychedelic research, with specific focus on workplace drug testing policies, and whether these risks merit additional...
The American Journal of Bioethics April 8, 2026 Osamu Muramoto
Peterson et al. (2026) provide insightful applications of the extended mind thesis (EMT) to the care of a person with dementia (PWD) (Clark and Chalmers 1998; Gallagher 2000; Clark 2008). The EMT i...
The American Journal of Bioethics 2026 Katherine Cheung, Brian D. Earp, Kyle Patch et al.
We are grateful to those who commented on our Target Article on ethical exceptionalism around psychedelics (see Box 1 for a summary of our main points) and to Cohen and Marks (2025) for their compl...
The American Journal of Bioethics July 30, 2025 Caleigh Propes, Katherine Cheung 1 citation
Informed consent aims, amongst other goals, to provide robust information to prospective participants on the risks and benefits that they may incur during a study. However, participant misconceptio...
The American Journal of Bioethics July 7, 2025 Veronika Gold 1 citation
I am requesting a correction to the article “Focused Bodywork as Facilitated Communication: Cautionary Perspectives on Touch in Psychedelic Therapy” by Neşe Devenot (2025). The article contains fac...
The American Journal of Bioethics July 1, 2025 Joel Janhonen, Juuso Kähönen, Joona Räsänen 5 citations
In his work on informed consent, Daniel Villiger (2025a) credibly argues that ignorance concerning the outcomes of transformative treatments need not undermine patient autonomy, while prohibitions ...
The American Journal of Bioethics January 13, 2025 Tahlia R. Harrison, Sonya C. Faber, Manzar Zare et al. 22 citations
The integration of psychedelic substances into modern Western therapeutic practice has sparked a critical examination of many topics including: efficacy of psychedelics to treat mental health diagnoses without psychotherapeutic intervention, what models of therapy to use, and ethical implications related to altered states of consciousness. Of utmost concern are issues of power dynamics leading...
The American Journal of Bioethics January 13, 2025 Jason B. Luoma, Jenna Lejeune 6 citations
Neitzke-Spruill et al. (2025) offer an important overview of the ethical considerations around the use of touch within psychedelic assisted therapies (PAT) and MDMA-assisted therapy (MDMA-AT). Thei...
The American Journal of Bioethics January 13, 2025 Keenan Davis, Roman Palitsky, Boadie W Dunlop et al. 3 citations
In their article “Psychedelic Medicine Exceptionalism,” Cohen and Marks (2025) aim to chart a middle course between two extreme positions—the Scylla and Charybdis of psychedelic “exceptionalism” an...
The American Journal of Bioethics January 13, 2025 Jamie Beachy, Willa Hall, Chantelle Thomas et al. 2 citations
As research therapists with hundreds of hours of clinical experience supporting adults with PTSD in Phase 3 trials of MDMA assisted-therapy (MAT), we appreciate the opportunity to respond to this s...
The American Journal of Bioethics January 13, 2025 Zak A. Kopeikin
Current research on psychedelic-assisted therapy (PAT) focuses on their potential to treat clinical psychiatric conditions such as treatment-resistant depression, anxiety, and PTSD. Presumably, if ...
The American Journal of Bioethics January 13, 2025 Edward Jacobs
Cheung et al. (2025) rightly argue that psychedelics should be subject to ethical and evidentiary standards consistent with clinical medicine at large, rather than exceptionalism based on their uni...
The American Journal of Bioethics January 2, 2025 Y. Tony Yang 4 citations
The recent surge in psychedelic-assisted therapy (PAT) research and anticipated Food and Drug Administration (FDA) approval of MDMA (methylenedioxymethamphetamine) and psilocybin treatments has bro...
The American Journal of Bioethics January 2, 2025 Bryony Insua‐summerhays, Edward Jacobs 3 citations
The role of touch in psychotherapy has been a topic of debate for several decades, now gaining renewed salience with the (re-)emergence of psychedelic-assisted therapy (P-AT), where altered states ...
The American Journal of Bioethics January 2, 2025 Khaleel Rajwani 2 citations
Cohen and Marks (2025) discuss medical exceptionalism within the context of psychedelic access pathways, noting that the medical model is just one of many possible approaches to using, understandin...
The American Journal of Bioethics 2025 Katherine Cheung, Brian D. Earp, Kyle Patch et al. 30 citations
When used clinically, psychedelics may appear unusual or even unique when compared to more familiar or long-standing medical interventions, prompting some to suggest that the ethical issues raised may likewise be exceptional. If that is correct, then perhaps psychedelics should be treated differently from other medical substances: for example, by being subjected to different ethical or...
The American Journal of Bioethics 2025 I. Glenn Cohen, Mason Marks 22 citations
Research on psychedelic medicines is experiencing a revival. Some clinicians, scientists, and ethicists believe that psychedelics are so different from other treatments that they warrant special consideration in how they are researched, regulated, commercialized, and administered. Others argue that psychedelic medicines show clinical potential, but they should be treated like other medical...
The American Journal of Bioethics 2025 Logan Neitzke-Spruill, Caroline Beit, Lynnette A. Averill et al. 19 citations
In August 2024, The U.S. Food and Drug Administration rejected Lykos Therapeutics, Inc.'s new drug application for midomafetamine with psychological intervention (MDMA-AT) to treat post-traumatic stress disorder (PTSD). Among the many issues raised during review was concern about a highly publicized case of alleged sexual misconduct by an unlicensed therapist during a Phase 2 study of MDMA and...
The American Journal of Bioethics 2025 Daniel Villiger 7 citations
The presence of unusual features in psychedelic treatments has led to the argument that these treatments are exceptional within medicine and should therefore also be treated as exceptional when ana...
The American Journal of Bioethics 2025 Neşe Devenot 3 citations
On August 9, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Lykos Therapeutics’ application for MDMA-assisted therapy (MDMA-AT), in alignment with the recommendation of its i...
The American Journal of Bioethics 2025 Jarrel de Matas, A. L. Mcguire, Hasan Yasin 3 citations
In their contribution to the rapidly developing field of research on psychedelic medicine, Glenn Cohen and Mason Marks shed light on a frequently overlooked but critical aspect of ethical considera...
The American Journal of Bioethics 2025 T. Findley 2 citations
of Votes 2020). Along with acknowledging that providing treatment for addiction is more beneficial than criminal charges, Measure 110 directed the state, through OHA, to create a statewide network of addiction recovery centers, providing ample grant funding to existing providers to do so
The American Journal of Bioethics 2025 Zachary J Verne, Natalie Gukasyan, Jeffrey S Zabinski 2 citations
In “Distinctive but not Exceptional: The Risks of Psychedelic Ethical Exceptionalism,” Cheung et al. (2025) elaborate the ways that psychedelics share individual ethical considerations with those o...